Macnary

Macnary is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the development of innovative targeted protein degradation (TPD) therapies. The company utilizes its proprietary PROTAC platform to design small molecules that selectively eliminate disease-causing proteins by leveraging the cellular ubiquitin-proteasome system. Macnary's lead candidate, MN-001, is an orally bioavailable androgen receptor (AR) degrader currently in Phase 1/2 clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company is also advancing MN-002, an estrogen receptor (ER) degrader for breast cancer, which has entered clinical development. Beyond its lead programs, Macnary is building a diverse pipeline of protein degraders targeting various oncology and autoimmune indications. The company is supported by leading venture capital firms and aims to address significant unmet medical needs in patients who have developed resistance to conventional therapies.